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Abstract
Background: In normal cells proliferation and apoptosis are tightly regulated, whereas in tumor cells the balance is
shifted in favor of increased proliferation and reduced apoptosis. Anticancer agents mediate tumor cell death via
targeting multiple pathways of programmed cell death. We have reported that the non-pathogenic, tumor
suppressive Adeno-Associated Virus Type 2 (AAV2) induces apoptosis in Human Papillomavirus (HPV) positive
cervical cancer cells, but not in normal keratinocytes. In the current study, we examined the potential of AAV2 to
inhibit proliferation of MCF-7 and MDA-MB-468 (both weakly invasive), as well as MDA-MB-231 (highly invasive)
human breast cancer derived cell lines. As controls, we used normal human mammary epithelial cells (nHMECs)
isolated from tissue biopsies of patients undergoing breast reduction surgery.
Results: AAV2 infected MCF-7 line underwent caspase-independent, and MDA-MB-468 and MDA-MB-231 cell lines
underwent caspase-dependent apoptosis. Death of MDA-MB-468 cells was marked by caspase-9 activation, whereas
death of MDA-MB-231 cells was marked by activation of both caspase-8 and caspase-9, and resembled a mixture
of apoptotic and necrotic cell death. Cellular demise was correlated with the ability of AAV2 to productively infect
and differentially express AAV2 non-structural proteins: Rep78, Rep68 and Rep40, dependent on the cell line. Cell
death in the MCF-7 and MDA-MB-231 lines coincided with increased S phase entry, whereas the MDA-MB-468 cells
increasingly entered into G2. AAV2 infection led to decreased cell viability which correlated with increased
expression of proliferation markers c-Myc and Ki-67. In contrast, nHMECs that were infected with AAV2 failed to
establish productive infection or undergo apoptosis.
Conclusion: AAV2 regulated enrichment of cell cycle check-point functions in G1/S, S and G2 phases could create
a favorable environment for Rep protein expression. Inherent Rep associated endonuclease activity and AAV2
genomic hair-pin ends have the potential to induce a cellular DNA damage response, which could act in tandem
with c-Myc regulated/sensitized apoptosis induction. In contrast, failure of AAV2 to productively infect nHMECs
could be clinically advantageous. Identifying the molecular mechanisms of AAV2 targeted cell cycle regulation of
death inducing signals could be harnessed for developing novel therapeutics for weakly invasive as well as
aggressive breast cancer types.
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Breast cancer is the most prevalent cancer in the world
and is the leading cause of cancer related death in
women (411,000 annual deaths represent 14% of female
cancer deaths) [1,2]. Breast cancer is also the most fre-
quent cancer of women (23% of all cancers) [1]. Routine
screening and early detection have reduced the inci-
dence of breast cancer, but despite optimal treatment,
about 30% of women with recurrent disease develop dis-
tant metastases [3]. Although multiple chemotherapeutic
strategies are currently in use for the treatment of breast
cancer [4], active treatment of patients is determined by
multiple factors such as the hormone-dependency of the
cancer [5], activation of specific oncogenes [6], invasive-
ness and metastases [7], subsequent drug resistance
[8-10] and the risk of potential toxicities with repeated
therapy [4,11]. Many patients are also subjected to com-
bination drugs, as no single agent offers a clear survival
advantage over another [4]. In addition, reliable biomar-
kers correlating response to chemotherapy and survival
have not been clearly defined [12]. As such, there is a
clinical need for breast cancer therapeutics which
potently target malignant cells resultant with identifiable
biomarkers, independent of the type of breast cancer
profile presented by the patient.
We have recently reported that the non-pathogenic,
tumor suppressive human Adeno-Associated Virus Type
2 (AAV2) induced apoptosis in both low and high-grade
Human Papillomavirus (HPV) positive cervical cancer
cell lines but not in normal keratinocytes [13]. AAV2
induced cell death correlated with the expression of
AAV2 non-structural Rep proteins and culminated in
DNA laddering and caspase-3 activation/cleavage [13],
both established hallmarks of apoptosis [14]. Since
AAV2 induced apoptosis also coincided with increased
S phase entry in HPV/AAV2 co-infected cells, our stu-
dies further suggested that coordinate manipulation of
both cell-cycle and apoptosis pathways by AAV2 has the
potential to suppress growth and proliferation of cervical
cancer cells [13]. Our work further provides a molecular
platform supporting earlier studies which suggested that
AAV2 seropositivity is negatively correlated with the
development of cervical cancer [15].
AAV2 has been shown to suppress DNA replication
and oncogenicity [16] of a number of viruses including
adenovirus [17], herpesvirus [18], pox virus [19] and
human papillomavirus (HPV) [20]. The AAV2 encoded
non-structural Rep78 protein has been shown to inhibit
in vitro cellular transformation mediated by papilloma-
viruses [21-24] and has been mapped to the ability of its
Rep proteins to downregulate transcription from the
papillomavirus early promoters [23,25,26]. Rep78 also
antagonizes expression and activity of cellular tumor
suppressors abrogated by adenovirus infections, such as
p53 [27], pRb [28] as well as cell cycle modulators such
as E2F [29], thereby curbing cell growth and prolifera-
tion. A recent report also demonstrated the ability of
AAV2 to induce a moderate degree of caspase activation
during adenovirus coinfection [30]. In animal models,
AAV2 was shown to suppress the growth of adenovirus
and herpesvirus induced tumors [31,32]. The tumor
suppressive functions of AAV2 are not restricted to
virus-virus interactions as AAV2 also suppressed cells in
culture transformed by activated oncogenes [33], selec-
tively killed carcinogen-treated cells [19,34] and targeted
uncontrolled cellular proliferation rates by implementing
cell cycle blocks, growth arrest and differentiation
[35-40]. These studies and our published report [13]
cumulatively led us to hypothesize that AAV2 also has
the potential to mediate death of breast cancer cells.
In the current study, we investigated the ability of
AAV2 to infect and induce apoptosis in a variety of
human breast cancer derived cell lines, representing a
range of breast cancer types graded upon hormone
dependency and aggressiveness: the luminal MCF-7
(ERa-positive) are weakly invasive and do not normally
metastasize to bone [41]; MDA-MB-468 (ERa-negative)
are weakly invasive and non-metastatic and were derived
from human breast adenocarcinoma [42]; and MDA-
MB-231 (ERa-negative) are highly invasive, basal cell
line [43] derived from metastatic (pleural effusion), infil-
trating ductal breast carcinoma [44]. The MDA-MB-231
cell line is highly metastatic which forms tumors when
injected into the mammary fat pads of immunocompro-
mised mice [44]. As controls, we used primary normal
human breast epithelial cells (nHMECs) isolated and
cultured from breast tissue samples from patients
undergoing breast reduction surgery. AAV2 infection
induced caspase-independent apoptosis in the MCF-7
and caspase-dependent apoptosis in the MDA-MB-468
and MDA-MB-231 cell lines. In contrast, normal human
mammary epithelial cells (nHMECs) were unaffected
upon infection with AAV2. Cell death of breast cancer
cells coincided with active AAV2 genome replication
and differential expression of AAV2 non-structural Rep
proteins: Rep78, Rep68 and/or Rep40 but not Rep52.
AAV2 induced cell death of the MCF-7 and MDA-MB-
231 lines was characterized by an increase in the num-
ber of cells with S phase DNA content whereas apopto-
tic MDA-MB-468 lines infected with AAV2 were
increasingly arrested in the G2 phase of the cell cycle.
Decreased cell viability in all three cell lines infected
with AAV2 was characterized by upregulated expression
of c-Myc and Ki-67, both proteins which are markers of
proliferation and c-Myc is also a pro-apoptotic protein.
Our results portray activation of distinct cell cycle and
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three breast cancer derived lines. Since the choice of
specific therapeutics for the treatment of breast cancer
is often determined by the aggressiveness of the cancer
presented by individual patients, our studies suggest that
AAV2 could have universal applicability for derivation




The MCF-7 [41], MDA-MB-468 [42] and MDA-MB-231
[43] cell lines have been previously described. Cells were
maintained in monolayer culture with E medium con-
taining 5% fetal bovine serum. Primary normal human
breast epithelial cells (nHMECs) were cultured from tis-
sues of patients undergoing breast reduction surgery,
using trypsin digestion at 37°C as previously described
[45]. The nHMECs were maintained in monolayer cul-
tures without feeder cells, with 154 medium (Cascade
Biologics, Portland, Oreg.), supplemented with antibio-
tics (Cascade Biologics) and human keratinocyte growth
supplement (Cascade Biologics). Patient breast tissue
samples were obtained using an Institutional Review
Board approved exemption status (Penn State University
College of Medicine, IRB No. 25284NHR).
Chemcials
Staurosporine, Cycloheximide and Tumor Necrosis Fac-
tor a were purchased from Sigma.
Viral stocks
AAV2 stocks were prepared in our laboratory using the
whole-cell lysate method, by banding twice on CsCl gra-
dients and determination of infectious titers as we have
described previously [13]. The AAV2 virus stocks were
tested for residual contamination with helper adenovirus
using the following methods. A 0.5 μl aliquot from the
CsCl gradient fractions was used to infect 293 cells in
24-well dishes. The AAV2 positive fractions exhibiting
low cytopathic effects were pooled, and heated at 56°C
for 30 min. The AAV2 stocks were then serially diluted
and further used to infect 293 cells in 60-mm dishes
and the presence of residual contaminating adenovirus
was visualized using plaque assays.
Cell synchronization and infection of cells
The MCF-7, MDA-MB-468, MDA-MB-231 and nHMEC
cell lines were grown to approximately 80% confluence,
trypsinized, and plated at a density of 1 × 10
6 cells in
100-mm plates in E medium. After plating, cells were
incubated between 10 and 12 h, at which time about
two-thirds or more of the cells are synchronized at the
G1 phase (without the addition of exogenous chemicals)
as previously described [13]. This time point was desig-
n a t e dt i m ez e r o .T h em e d i u mw a sa s p i r a t e df r o mt h e
plates, and infections were carried out using AAV2 at a
multiplicity of infection( M O I )o f0 . 0 2( u s i n gA A V 2
MOIs of 10, 20, 30 and 100 yielded similar results). The
infections were performed by diluting the AAV2 stocks
into 1 ml of E medium without serum and used for
infection of cells. Mock infections were performed using
1 ml of E medium without serum. Plates were incubated
at 37°C for 2 h with intermittent swirling. At the end of
the incubation, residual medium was aspirated from the
plates and replaced with 10 ml of fresh E medium sup-
plemented with serum. Virus infected and mock infected
cells were collected at t = 0 and day 1 through day 7
post-infection with AAV2. Using this method, the
nHMECs could be passaged and viably cultured between
5 to 7 days due to their inherent primary cell growth
characteristics. Both mock-infected and AAV2-infected
cell samples were trypsinized, inactivated with the addi-
tion of serum, pelleted, and stored at -70°C until further
manipulations. Additionally, on day 2 and day 5 (when
cells were approximately 80% confluent), both mock and
AAV2 infected cells were passaged at a ratio of 1:2 and
plated in fresh E medium.
Southern blot analysis of AAV2 DNA replication
A5μg aliquot of the isolated low molecular weight
DNA was separated by electrophoresis in a 0.8% TAE
agarose gel followed by transferring to GeneScreen Plus
membranes (New England Nuclear Research Products,
Boston, MA), as previously reported [46]. Samples were
probed with
32P-labeled total AAV2 genomic DNA
probe generated by random primer extension using
methods previously described [46].
Transfection assays
Cells were transfected using the calcium phosphate
method as previously described [47]. Both N,N-bis(2-
hydroxyethyl)-2-aminoethane-sulfonic acid (BES) and
CaCl2 were purchased from Sigma-Aldrich. Briefly, a
stock solution of 2.5 M CaCl2 was prepared and filter
sterilized through a 0.22 μm filter, and stored at -20°C.
A stock solution of 2× BES-buffered saline (2× BBS) was
prepared containing 50 mM BES, 280 mM NaCl, and
1.5 mM Na2HPO4. The pH was adjusted to pH 6.95
with HCl, filter sterilized through a 0.22 μmf i l t e ra n d
stored at -20°C. Cells were seeded 24 h prior to trans-
fection using 10
6 cells per 100-mm dish in E-medium
containing 5% FBS without the addition of antibiotics.
The mixture for transfecting cells was prepared as fol-
lows: 30, 60 and 100 μg of the plasmid containing the
full-length AAV2 genome was added to deionized water
up to a volume of 450 μl, followed by addition of 50 μl
of 2.5 mM CaCl2. Finally, 500 μlo f2 ×B B Sw a sa d d e d
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room temperature for 10-20 min. To determine the
transfection efficiency, 30 μg of a green fluorescent pro-
tein (GFP) expression vector (Clontech) was transfected
alone or co-transfected with the AAV2 genome into
cells and used as a surrogate marker for delivery of the
unlabeled AAV2 plasmid DNA where indicated. Trans-
fection controls were essentially cells treated with the
calcium phosphate precipitate without the addition of
plasmid DNA. The 1 ml DNA suspension was mixed by
gently inverting and added to the 100 mm culture
dishes dropwise, followed by swirling the plates to
evenly distribute the DNA precipitate. Following 24 hr
of incubation, the medium was removed and cultures
were rinsed twice using E-medium without serum and
finally replaced with E-medium supplemented with 5%
FBS without antibiotics and incubation was further con-
tinued for 24 hr. These samples were designated as the
48 hr samples post-transfection. Another set of cells was
further incubated for 5 days and designated as the 7 day
samples post-transfection. At the end of the designated
incubation times cells were harvested by trypsinization,
washed with phosphate-buffered saline (PBS) and fixed
in 70% ethanol and prepared for FACS analysis using
protocols described below.
Preparation of total cellular protein extracts and Western
blotting
Total protein extracts were prepared from the mono-
layer cultures and quantitated using the Lowry Method
as previously described [13,48]. For detecting cell cycle
proteins, a total of 60 μg whole cell extract was used in




INK4. To detect pRb and p53 protein
expression, 30 μg of whole cell extracts were used. Pro-
tein extracts were applied to sodium-dodecyl sulfate
(SDS)-polyacrylamide (SDS-PAGE) gel (acrylamide/bisa-
crylamide ratio, 30:0.8). Gel compositions for resolving
various proteins are as follows. A 12% gel was used to
detect p21
WAF1, 15% gel for p16
INK4, 10% gel for
p27
KIP1, and 7.5% SDS-PAGE gel for pRb and p53. Poly-




pRb (Santa Cruz) were each used at a dilution of 1:2000
to detect the respective proteins, and have been
described previously [13,48]. A monoclonal antibody
against p53 (Oncogene) was used at a dilution of 1:1000
for detecting the protein and has been described pre-
viously [13,48].
To detect c-Myc and Ki-67 protein expression, 60 μg
of whole cell extracts were used. Monoclonal antibodies
against c-Myc (Santa Cruz) were used at a dilution of
1:500 and polyclonal antibodies against Ki 67 (Santa
Cruz) were used at a dilution of 1:2000. For detecting
involucrin, K-10 and K-14 expression, 5 μg of whole cell
extract was used. The mouse monoclonal involucrin
antibody (clone SY; Sigma) and K-10 antibody (Bio-
Genex) were used at a dilution of 1:7000. The mouse
monoclonal antibody (Sigma) was used at a dilution of
1:3000.
To detect apoptosis regulatory proteins, 60 μgo f
whole cell extracts were used. To detect the pro-caspase
form of caspase-3, proteins were resolved in a 10% SDS-
PAGE gel and detected with caspase-3 rabbit monoclo-
nal antibody (Cell Signaling Technology) and used at a
dilution of 1:1000. To detect the 19 kDa and 17-kDa
cleaved caspase-3 forms, proteins were resolved in a
15% SDS-PAGE gel and detected with rabbit polyclonal
antibody against cleaved caspase-3 (Cell Signaling Tech-
nology) and used at a dilution of 1:1000. To detect the
pro-caspase form of caspase-6, proteins were resolved in
a 10% SDS-PAGE gel and to detect the cleaved form of
caspase-6, proteins were resolved in a 15% SDS-PAGE
gel and detected with a rabbit polyclonal antibody (Cell
Signaling Technology) used at a dilution of 1:1000. To
detect both the pro- and cleaved forms of caspase-7,
caspase-8 and caspase-9, proteins were resolved in a
10% SDS-PAGE gel. Caspase-7 was detected with a
mouse monoclonal antibody (Cell Signaling) and used at
a dilution of 1:1000. Caspase-8 was detected with a
mouse monoclonal antibody (Alexis Biochemicals) and
used at a dilution of 1:2000. Caspase-9 was detected
with a rabbit polyclonal antibody (Cell Signaling) and
used at a dilution of 1:1000. To detect the pro- and
cleaved forms of PARP, proteins were resolved in a 7.5%
SDS-PAGE gel and detected with a rabbit monoclonal
antibody (Cell Signaling) and used at a dilution of
1:1000. Proteins were detected using enhanced chemilu-
minescence (ECL) method (Perkin Elmer) as per manu-
facturer’s instructions.
Cell viability assay and flow cytometric analysis of DNA
content
MCF-7, MDA-MB-231, MDA-MB-468 cultures were
synchronized and infected with AAV2 as described
above. At each time point, cell samples were collected at
t = 0 and days 1 through 7. On day 2 and day 5, both
mock and AAV2 infected cells were passaged 1:2 as
described above. Both mock and AAV2 infected cell
samples were trypsinized, inactivated with the addition
of serum, and counted using trypan blue exclusion
using standard protocols.
For performing flow cytometry, mock and AAV2
infected cells were prepared for analysis as previously
described [48]. Briefly, MCF-7, MDA-MB-231 and
MDA-MB-468 cells were synchronized and infected
with AAV2 as described above. Mock and AAV2
infected cells were sampled at t = 0 and from day 1
through day 7, with passaging on day 2 and day 5 as
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z a t i o n ,w a s h e dw i t hP B S ,f ixed in 70% ethanol, and
stored at -20°C. The fixed cells were washed in PBS and
then resuspended in PBS containing 0.1% Triton X-100
(Sigma), 200 μg/ml DNase-free RNase A (Boehringer
Mannheim), and 100 μg/ml of propidium iodide (Sigma)
for 30 min at 37°C. Flow cytometric analysis of 10
6 cells
was carried out in a fluorescence-activated cell sorter
(FACS), and the percentages of cells in the G1, S and
G2/M phases of the cell cycle were determined using
the Cell Quest program of Becton Dickinson. Data were
analyzed with the Mod Fit LT program.
Results
AAV2 infection induces apoptosis in the breast cancer
derived cell lines but not in normal breast epithelial cells
Multiple studies, including our published report [13],
have documented the anti-proliferative nature of AAV2.
We further wanted to examine the possibility that
AAV2 infection could also suppress growth and prolif-
eration of breast cancer derived cells. In the current
study, we used three different human breast cancer
derived cell lines representing a range of breast cancer
types: MCF-7 (ER
+), MDA-MB-468 cells (ER
-)a n d
MDA-MB-231 (ER
-) cells. As controls, we used primary
normal human breast epithelial cells (nHMECs) isolated
and cultured from breast tissue samples from patients
undergoing breast reduction surgery.
The MCF-7, MDA-MB-468, MDA-MB-231 and
nHMEC cells were synchronized as described in Materi-
als and Methods, when approximately two-thirds or
more of the cells were in the G1 phase of the cell cycle
[13,48]. Under our culture conditions, this is the maxi-
mum level of synchronization that we normally achieve
with or without the addition of exogenous chemicals.
Synchronized cultures were infected with AAV2 using
a nM O Io f0 . 0 2( u s i n gA A V 2M O I so f1 0 ,2 0 ,3 0a n d
100 yielded similar results). Both AAV2-infected and
mock-infected cells were grown to 80% confluence (day
2), at which time the cells were passaged at a ratio of
1:2, followed by a period of further growth and passa-
ging again at a 1:2 ratio on day 5. On day 5, each of the
AAV2 infected breast cancer cell lines showed growth
retardation, and eventually culminated in complete
apoptotic cell death as evidenced by visualizing the
DNA laddering in the MCF-7 and MDA-MB-468 cells
(Figure 1A and 1B), and a mixture of DNA laddering
and non-specific DNA degradation in the MDA-MB-231
cells (Figure 1C). In contrast, AAV2 infection of
nHMECs did not induce DNA laddering or degradation
(Figure 1D), but both control and AAV2 infected
nHMECs eventually underwent senescence. Due to their
inherently primary growth characteristics in culture,
nHMECs isolated from patient biopsies have a limited
l i f e - s p a ni nc u l t u r e .T h eD N A laddering experiments
were performed with a batch of nHMECs which was
limited to 5 days in culture. The inability of AAV2 to
induce DNA laddering or degradation in the normal
epithelial cells tested was reproducible in multiple
batches of nHMECs isolated from individual patients.
Using western blot analysis we also confirmed the
epithelial origin of the different isolates of nHMECs by
detecting the expression of cytokeratins which are
k n o w nt ob ee x p r e s s e di nt h en o r m a lb r e a s te p i t h e l i a l
cells, such as K-10 [49], K-14 [50] and involucrin [51]
(Figure 1E). Qualitative differences between the different
batches of nHMECs isolated did not affect their ability
to be infected with AAV2 as was further verified by per-
forming other assays as described elsewhere in this
manuscript. We have similarly reported that AAV2 also
specifically targets HPV positive cervical cancer cells
representing both low and high cancer grades but not
primary human keratinocytes [13].
Apoptosis induction in the three breast cancer lines
tested was also portrayed as a steady decrease in cell
viability over the 7 day period post-infection with AAV2
(Figure 2). On day 8, we observed a 100% death of each
of the AAV2 infected cell lines (data not shown). These
results suggest the specificity of AAV2 targeted cell kill-
ing of the breast cancer cells regardless of breast cancer
grade. Since complete cell death was accomplished
using an initial MOI of 0.02, this meant that on average
1 out of 50 cells were infected. Therefore, the mechan-
ism of cell killing was potentially mediated by a “by-
stander” type of effect, in which one cell undergoing cell
death releases cytotoxic metabolites, cellular proteins, or
in this study, perhaps AAV2 encoded proteins, which
are able to spread to surrounding non-infected cells
through cellular gap junctions, and mediate cell killing,
as has been previously described [52,53].
AAV2 infection of breast cancer cells results in Rep
protein expression and genome replication which
culminates in apoptosis induction
AAV2 encodes four non-structural proteins: Rep78 and
Rep68, which regulate multiple viral functions includ-
ing DNA replication and transcription; and Rep52 and
Rep40, which are involved in packaging of viral gen-
omes into capsids [16]. The Rep78, Rep68 and Rep40
proteins were differentially expressed in the multiple
breast cancer lines infected with AAV2 (Figure 3A, B
and 3C) but Rep52 expression could not be deter-
mined in any of the virus infected cell lines. In con-
trast, AAV2 infected nHMECs did not express any Rep
proteins (Figure 3D). The kinetics of Rep protein
expression and their relative abundance varied between
the different breast cancer lines. While Rep78 and
Rep68 expression was clearly detected in AAV2
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Page 5 of 24Figure 1 AAV2 induced DNA laddering/degradation in multiple breast cancer cell lines. (A) MCF-7, (B) MDA-MB-468, (C) MDA-MB-231 and
(D) nHMECs monolayer cultures were synchronized in G1, followed by infection with AAV2 at an MOI of 0.02. Cell pellets were collected each
day over a seven day period for the breast cancer cell lines, and over a five day period for the nHMECs. The breast cancer cell lines were
passaged 1:2 on day 2 and day 5, and on day 2 for nHMECs. DNA laddering assays were performed by isolating low-molecular weight DNA
using protocols described herein. Twenty micrograms of DNA were resolved in a 1% agarose Tris-Borate-EDTA gel and stained with ethidium
bromide. Results shown are representative of three individual experiments. t, time; +, AAV2 infected; -, control. DNA ladders are indicate the
following base-pair fragments starting at the top: 23941, 9416, 6557,4361, 2322, 2027, 1353, 1073, 872, 603, 310. (E) nHMECs cultured from
multiple patient breast tissue biopsies were used to prepare whole cell extracts. Five micrograms of the extract was used for western blot
analysis. Cytokeratin markers Involucrin, K10 and K14 were detected using antibodies as described in Materials and Methods.
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Page 6 of 24Figure 2 Cell viability as a measure of AAV2 induced cell death in the breast cancer cell lines. (A) MCF-7, (B) MDA-MB-468 and (C) MDA-
MB-231 cells were infected with AAV2. Trypan blue exclusion was used to determine the growth inhibitory effect of AAV2 on the monolayer
cultures of the different breast cancer cell line cultures. Results shown are representative of three individual experiments. t = time. Arrows
indicate days when the cells were passaged at a ratio of 1:2.
Figure 3 AAV2 induction of apoptosis/cell death in the different breast cancer lines correlates with Rep protein expression.F o r
detecting Rep proteins in Western blots, total protein extracts were prepared as we have previously described [13,48]. Sixty micrograms of total
protein extracts from AAV2 infected and control (A) MCF-7, (B) MDA-MB-468, (C) MDA-MB-231 and (D) nHMECs monolayer cultures were
resolved in a 7.5% SDS-polyacrylamide gel electrophoresis gel and detected with an AAV2 Rep-specific antibody (Progen). Results shown are
representative of three individual experiments. t, time; +, AAV2 infected; -, control. Double asterisks (**) indicate dimer form of protein, single
asterisk (*) indicates the monomer form.
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ing up to day 7 (Figure 3A), in the AAV2 infected
MDA-MB-231 cells only Rep78 expression was barely
detectable on day 3, with progressive increase in both
Rep78, Rep68 and Rep40 expression at later time
points during the same time-course (Figure 3C). Rep
protein expression on day 3 preceded apoptotic DNA
laddering in the MCF-7 cells, and DNA laddering/
degradation in MDA-MB-231 cells which was observed
on day 4, but increased in subsequent days (compare
Figure 3 to Figure 1). Our results also agree with pre-
viously published reports which showed that the
expression of Rep78 alone was shown to be sufficient
for induction of apoptosis in HL60 cells in vitro [54].
In contrast to the other two breast cancer cell lines, in
the AAV2 infected MDA-MB-468 cells, only Rep78
expression could be determined with clarity on day 6
and day 7 (Figure 3B), with potentially Rep68 also
being expressed (Figure 3B). The antibody used for
detecting the Rep proteins bound to a cross-reacting
band in the control lanes of MDA-MB-468 cells which
resolved near to Rep68 in the AAV2 infected samples
(Figure 3B), but which was less intense than the Rep68
band. In MDA-MB-468 cells, apoptotic DNA laddering
was observed on day 4 (Figure 1B), but Rep78 protein
was not clearly detected until days 6 and 7 (Figure 3B).
Since AAV2 genome replication was detected as early
as day 4 in the virus infected cells (Figure 4B), it is
possible that under these conditions, in the MDA-MB-
468 cells, low levels of Rep protein were expressed ear-
lier than day 6 but expression was at the limits of
detection using the techniques used.
Figure 4 Southern blot analysis of AAV2 genome replication in breast cancer cell lines. Southern blot analysis to detect 4.7 kb AAV2
replicative form monomer representing active genome replication in AAV2 infected (A) MCF-7, (B) MDA-MB-468, (C) MDA-MB-231 breast cancer
cells and (D) nHMECs. A total of 5 μg of total DNA was then detected with AAV2 genomic DNA as probe as previously described [46]. One
hundred nanograms of total DNA isolated from cells was used as loading control (bottom). Results shown are representative of three individual
experiments. t, time; +, AAV2 infected; -, control.
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all three cell lines (Figure 3), which is not uncommon
since others have also reported finding the high molecu-
lar weight Rep78 complexes, which are essentially Rep-
Rep protein aggregates containing two to six Rep pro-
teins which persist in sodium dodecyl sulfate (SDS)
[55,56]. We have also detected these high molecular
weight Rep78 complexes in HPV/AAV2 co-infected cer-
vical cancer cells undergoing apoptosis [13].
To rule out the possibility that the failure of AAV2
infected nHMECs to express Rep proteins was due to
the inability of the virus to infect the normal breast
epithelial cells, we performed Southern blot analysis to
detect the status of AAV2 DNA replication. The 4.7 kb
replicative form DNA monomer was detectable in the
three AAV2 infected breast cancer cell lines tested
(Figure 4A-C), but not in the nHMECs (Figure 4D). The
inability of AAV2 to replicate in nHMECs was also con-
firmed by the absence of Rep protein expression in
these cells (Figure 3D). Thus, the failure of AAV2 to
productively infect nHMECs could lead to failure of Rep
proteins being expressed and subsequently undergo
apoptosis.
To address the possibility that AAV2 failed to produc-
tively infect nHMECs and induce apoptosis, we analyzed
the effect of physically delivering the full-length AAV2
genome into nHMECs using standard calcium phos-
phate DNA co-precipitation and transfection protocols.
We have previously utilized this method to show that
transfection of the AAV2 genome into HPV positive
cells resulted in cell death [13], whereas normal human
keratinocytes similarly transfected were unaffected [13].
In the current study, we transfected 30, 60 and 100 μg
of the full-length cloned AAV2 genome into the
nHMECs and MCF-7 cells. The same AAV2 clone was
also used for production of the AAV2 virus stocks. To
determine the transfection efficiency, we also co-trans-
fected 30 μg of a green fluorescent protein (GFP)
expression vector (Clontech) as a surrogate marker for
the delivery of the unlabeled AAV2 genome into the
two cell types. In our hands, the efficiency of the trans-
fection protocol performed with 30 μgo ft h eG F P
expression vector alone routinely resulted in an average
of 20% of each cell type being GFP positive (Figure 5A
and 5C), which is within the efficiency range reported
for keratinocytes in published studies [57,58]. At 48 h
post-transfection, both the MCF-7 cells and nHMECs
co-transfected with the AAV2 genome/GFP expression
vector expressed numbers of GFP-positive cells that
were approximately equal to the number of cells in each
r e s p e c t i v et y p ee x p r e s s i n gG F Pa l o n e( F i g u r e5 Aa n d
5C). At this time point, growth/adherence of the AAV2-
transfected MCF-7 cells and nHMECs was similar to the
GFP only control transfected cells (Figure 5A). These
results are in contrast to our earlier studies which
clearly showed cell death of the AAV2-transfected HPV
cells at 48 h post-transfection but not the primary
human keratinocytes [13]. An alternative possibility was
that AAV2 transfection of breast epithelial cells result in
delayed cellular effects which required incubations
beyond the 48 h time-point post-transfection. To further
determine whether AAV2 transfection into the MCF-7
cells and nHMECs resulted in identifiable early and late
changes, we performed cell cycle analysis. We have pre-
viously reported the ability of AAV2 infection to modu-
late the cell cycle machinery in cervical cancer cells at
both early and late times post-infection [13,48]. We
determined the percentage distribution of the AAV2
genome transfected MCF-7 and nHMECs in G1, S, G2
and M phases of the cell cycle at 48 h and 7 days post-
transfection. As mentioned above, nHMECs could be
viably cultured up to 7 days. At 48 hr post-transfection,
AAV2 transfected MCF-7 cells showed a sustained
increase in the percentage of cells with S phase DNA
content compared to control transfected- as well as GFP
only-transfected cells (Figure5 B ) .T h i so b s e r v a t i o nw a s
s i g n i f i c a n t ,s i n c ew eh a v ep r e v i o u s l ys h o w nt h a tA A V 2
infected HPV positive cells increasingly entered into S
phase which was followed by Rep protein expression
and apoptosis induction [13] and was also shown to be
true for AAV2 infected MCF-7 cells (discussed below).
In contrast, at 7 days post-transfection, the percentage
of MCF-7 cells in S phase was similar to controls (Fig-
ure 5B), but an increased percentage of dead cells was
indicated by the appearance “debris”, essentially com-
posed of damaged cell membranes which weakly stain
with propidium iodide as a result of DNA loss. There-
fore, detection of damaged cellular membranes was a
measurable consequence of AAV2 induced cell death. In
contrast, at 48 h post-transfection, AAV2 transfected
nHMECs displayed S phase fraction of cells which was
similar to control transfected cells (Figure 5D), and
these levels did not change after 7 days post-transfection
(Figure 5D). Additionally, AAV2 induced cellular mem-
brane damage ("debris”) was not observed at either 48 h
or 7 day time-points post-transfection (compare Figure
5B with Figure 5D). Our results cumulatively suggest
that although AAV2 is capable of infecting nHMECs it
is unable to establish a persistent infection. These
results essentially duplicated our earlier observations
that AAV2 was unable to establish a persistent infection
in primary keratinocytes [13]. The observed differences
are potentially due to sensitivities of the cancer lines to
AAV2 mediated gene transcription compared with pri-
mary cells. To rule out the possibility that qualitative
differences between the different batches of nHMECs
isolated affected their ability to be transfected with
A A V 2 ,w ep e r f o r m e dt h ev i r us infection and genome
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Page 9 of 24Figure 5 Calcium-phosphate transfection of the cloned AAV2 genome into MCF-7 cells and nHMECs. (A) MCF-7 cells. Untransfected cells,
GFP-only controls (+GFP), and GFP vector and AAV2 genome co-transfected cells (+GFP/+AAV2). All images were captured with a 20× objective.
(B) MCF-7 cells. Fluorescent Activated Cell Sorting (FACS) Analysis of transfected cells analysed at 48 h and 7 days post-transfection. Percentages
of different cell cycle phases are represented in the G1, S and G2 fractions. Percentage denoting “Debris” is indicative of DNA damage induced
cell death/loss of membrane integrity. (C) nHMECs. Untransfected cells, GFP-only controls (+GFP), and GFP vector and AAV2 genome co-
transfected cells (+GFP/+AAV2). All images were captured with a 20× objective. (D) nHMECs. Fluorescent Activated Cell Sorting (FACS) Analysis of
transfected cells analysed at 48 h and 7 days post-transfection. Percentages of different cell cycle phases are represented in the G1, S and G2
fractions.
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Page 10 of 24transfection experiments with multiple batches of cells
and obtained similar results.
The inability of nHMECs to undergo apoptosis was of
interest from a mechanistic point of view, since a poten-
tial concern was the possibility that the nHMECs had
acquired modifications which rendered them resistant to
apoptosis. To show that the cells were still sensitive to
apoptotic signals, we treated the nHMECs with stauros-
porine (1 μM), which has been shown to activate the
instrinsic pathway of apoptosis, and a combination of
cycloheximide (CHX) (10 μg/ml) and Tumor Necrosis
Factor-Alpha (TNFa) (20 ng/ml), which has been shown
to activate the extrinsic pathway of apoptosis. Treatment
with both staurosporine and CHX/TNFa resulted in
increased accumulation of the sub-G1 cell population as
shown in the FACS analysis, and which is an indicator
of apoptosis (Figure 6A). Further, staurosporine
mediated cleavage of caspase-9, a marker for the intrin-
sic, and CHX/TNFa mediated cleavage of caspase-8, a
marker for the extrinsic pathway of apoptosis (Figure
6B). These results show that the inability of nHMECs to
undergo AAV2 mediated cell death was not due to the
acquisition of death resistance pathways.
We also analyzed the ability of transfected Rep78 pro-
tein expression construct to induce cell death of
nHMECs. For these experiments, 30, 60 and 100 μgo f
the Rep78 expression vector under control of the CMV
promoter (a kind gift of A. Marcello) [59] was trans-
fected into nHMECs. We performed FACS analysis of
the transfected cells both at 48 h and 7 days post-trans-
fection. Neither early or late time points post-transfec-
tion showed the ability of Rep78 to induce cell death to
any measurable degree (Figure 6C) (and compare Figure
5 with Figure 6). The inability of Rep78 to induce cell
death of nHMECs could suggest the possibility that
Rep78 alone is insufficient for death induction and per-
haps the other Rep proteins need to be co-expressed for
apoptosis to occur.
AAV2 Rep protein expression results in activation of both
caspase-dependent and -independent pathways of
apoptosis induction in the multiple breast cancer lines
Apoptotic cell death occurs due to activation of two sig-
naling pathways: first, the extrinsic, or receptor-
mediated pathway, and secondly, the intrinsic or mito-
chondrial pathway [14]. Two groups of caspases charac-
terize these pathways: the initiator (caspase-8, -9, and
-10) and executioner (caspase-3, -6, -7) caspases. Initia-
tor caspases cleave and activate executioner caspases,
which in turn process cellular substrates which orches-
trate the biochemical execution of cell death [60]. We
have previously shown that AAV2 induction of apopto-
sis in HPV positive cervical cancer cells was correlated
with caspase-3 activation/cleavage [13]. In the current
study, it was of interest to determine whether AAV2
induction of apoptotic cell death in the three different
breast cancer cell lines was due to activation of common
pathways.
The endogenous caspase-3 protein is abundantly
expressed in the MDA-MB-468 [61] and MBA-MB-231
[62] cell lines, but the MCF-7 cells do not express cas-
pase-3 due to a 47-bp deletion within the corresponding
gene [63]. To investigate which of the executioner cas-
pases were cleaved upon AAV2 induced apoptosis in
the breast cancer lines, we examined expression of cas-
pases -3, -6 and -7 in total protein extracts. Since the
MCF-7 cells do not express caspase-3, we examined the
expression levels of other executioner caspases, caspase-
6 and caspase-7, in mock and AAV2 infected cells (Fig-
ure 7). Neither executioner caspases -6 or -7 showed
any significant or consistent changes in the levels of the
full-length proteins (Figure 7), and their cleaved forms
could not be detected (data not shown). Failure to
observe cleaved forms of either executioner caspases -6
and -7 was unexpected since the AAV2 infected MCF-7
cells additionally displayed the 89 kDa cleaved fragment
of PARP (Figure 7), a DNA repair enzyme which is gen-
erally inactivated by cleavage from one of the execu-
tioner caspases [64]. At the same time, apoptotic DNA
laddering was observed in AAV2 infected cells (Figure
1A). It is possible that in AAV2 infected MCF-7 cells,
other non-caspase dependent pathways of PARP inacti-
vation potentially play a role in cell death, such as cal-
pain-dependent PARP cleavage [65]. Furthermore, in
our hands, apoptosis induction in AAV2 infected MCF-
7 cells could not be correlated with cleavage of either
initiator caspases -8 or -9 (Figure 7). Cumulatively, our
results in the current study indicate that AAV2 targets
caspase-independent pathway(s) of apoptosis in the
virus infected MCF-7 cells.
In contrast to the MCF-7 cells, both the initiator and
executioner caspases were differentially cleaved in the
AAV2 infected MDA-MB-468 cells. In these cells,
AAV2 regulated PARP cleavage clearly correlated with
cleavage of caspase-3 (Figure 8) and apoptotic DNA lad-
dering (Figure 1B). AAV2 infected cells displayed the 17
kDa cleaved form of caspase-3 which was clearly visible
starting on day 5 post-infection (Figure 8). In contrast
to caspase-3, the 15 kDa cleaved form of caspase-6 was
observed in both control and AAV2 infected MDA-MB-
468 cells, although the levels of cleaved caspase-6 were
higher in the virus infected cells compared with controls
(Figure 8). Likewise, both the cleaved and uncleaved
forms of caspase-7 were observed in these cells regard-
less of AAV2 infection, but their respective amounts
could not be clearly correlated with AAV2 induced cell
death (Figure 8). Therefore, PARP cleavage could be
mediated by either caspase-3 or caspase-6 in the AAV2
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Page 11 of 24Figure 6 Determining the ability of nHMECs to undergo chemically induced and Rep78 induced apoptosis. (A) nHMECs were treated
with either staurosporine (1 μM) to activate the instrinsic pathway, and a combination of cycloheximide (CHX) (10 μg/ml) and Tumor Necrosis
Factor-Alpha (TNFa) (20 ng/ml) to activate the extrinsic pathway of apoptosis. Cells were treated for 24 h, harvested prepared for FACS analysis,
and 10
6 cells were analyzed by flow cytometry. Top panel denotes histograms of the DNA distribution representing percentages of cells in the
G1, S and G2 phases of the cell cycle denoted in the bottom panel, as determined using the Cell Quest program of Becton Dickinson. Data
were analyzed with the Mod Fit LT program. (B) Staurosporine treatment induced cleavage of caspase-9 and CHX/TNFa treatment induced
cleavage of caspase-8 as determined from western blot analysis. (C) Calcium-phosphate transfection of the cloned Rep78 expression construct
under CMV promoter control into nHMECs. Untransfected control, GFP-only controls (+GFP), and GFP vector and CMV-Rep78 construct co-
transfected cells (+GFP/Rep78). Top panel denotes histograms of the DNA distribution representing percentages of cells in the G1, S and G2/M
phases of the cell cycle denoted in the bottom panel, as determined using the Cell Quest program of Becton Dickinson. Data were analyzed
with the Mod Fit LT program. Analysis of transfected cells analyzed at 48 h and 7 days post-transfection.
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Page 12 of 24infected MDA-MB-468 cells. In these cells, AAV2
induced apoptosis was further correlated with caspase-9
cleavage to its 35 kDa form but caspase-8 was
unchanged (Figure 8). AAV2 mediated activation of cas-
pase-9 suggested virus targeted disruption of mitochon-
drial functions and cytochrome c release. Our results
clearly indicate AAV2 mediated targeting of the intrinsic
pathways of apoptosis in the MDA-MB-468 cells.
In comparison with both the MCF-7 and MDA-MB-
468 cell lines, the steady-state protein levels of both
uncleaved and cleaved forms of caspases-3, -6 and -7
declined in the AAV2 infected MDA-MB-231 cells com-
pared with mock infected cells (Figure 9). The MDA-
Figure 7 AAV2 induction of apoptosis in MCF-7 cells results in
PARP cleavage independent of caspase activation. MCF-7
monolayer cell cultures were synchronized in G1, followed by
infection with AAV2. Cell pellets were collected each day over a 7
day period. Cells were passaged 1:2 on day 2 and day 5. Detection
of caspases and their cleavage/activation was performed by
Western blotting. Total protein extracts were prepared as described
previously [48]. Sixty micrograms of total protein extracts from AAV2
infected MCF-7 and control cells were resolved in SDS-
polyacrylamide gel electrophoresis (PAGE) gels. To detect the 35
kDa pro-caspase form of caspase-6, proteins were resolved in a 10%
SDS-PAGE gel and detected with a rabbit polyclonal antibody (Cell
Signaling Technology). To detect both the pro- and cleaved forms
of caspase-7, caspase-8 and caspase-9, proteins were resolved in a
10% SDS-PAGE gel. The 35 kDa pro-caspase form of caspase-7 was
detected with a mouse monoclonal antibody (Cell Signaling). The
58 and 56 kDa forms of caspase-8 were detected with a mouse
monoclonal antibody (Alexis Biochemicals). The 47 kDa pro-caspase
form of caspase-9 was detected with a rabbit polyclonal antibody
(Cell Signaling). To detect the pro- (116 kDa) and cleaved- (89 kDa)
forms of PARP, proteins were resolved in a 7.5% SDS-PAGE gel and
detected with a rabbit monoclonal antibody (Cell Signaling).
Figure 8 AAV2 induction of apoptosis in MDA-MB-468 cells
results in PARP cleavage following activation of caspases of
the intrinsic pathway. MDA-MB-468 monolayer cell cultures were
synchronized in G1, followed by infection with AAV2. Cell pellets
were collected each day over a 7 day period. Cells were passaged
1:2 on day 2 and day 5. Detection of caspases and their cleavage/
activation was performed by Western blotting. Total protein extracts
were prepared as described previously [48]. Sixty micrograms of
total protein extracts from AAV2 infected and control MDA-MB-468
cells were resolved in SDS-polyacrylamide gel electrophoresis (PAGE)
gels. To detect the 35 kDa pro-caspase form of caspase-3, proteins
were resolved in a 10% SDS-PAGE gel and detected with caspase-3
rabbit monoclonal antibody (Cell Signaling Technology). To detect
the17-kDa cleaved caspase-3 forms, proteins were resolved in a 15%
SDS-PAGE gel and detected with rabbit polyclonal antibody against
cleaved caspase-3 (Cell Signaling Technology). To detect the 35 kDa
pro-caspase form of caspase-6, proteins were resolved in a 10%
SDS-PAGE gel and to detect the 15 kDa cleaved form of caspase-6,
proteins were resolved in a 15% SDS-PAGE gel and detected with a
rabbit polyclonal antibody (Cell Signaling Technology). To detect
both the pro- and cleaved forms of caspase-7, caspase-8 and
caspase-9, proteins were resolved in a 10% SDS-PAGE gel. The 35
kDa pro-caspase form and the 30 kDa and 20 kDa cleaved forms of
caspase-7 was detected with a mouse monoclonal antibody (Cell
Signaling). Caspase-8 was detected with a mouse monoclonal
antibody (Alexis Biochemicals). The 47 kDa pro-caspase and 35 kDa
cleaved of caspase-9 was detected with a rabbit polyclonal
antibody (Cell Signaling). To detect the pro- (116 kDa) and cleaved-
(89 kDa) forms of PARP, proteins were resolved in a 7.5% SDS-PAGE
gel and detected with a rabbit monoclonal antibody (Cell
Signaling).
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Page 13 of 24MB-231 cells incidentally maintained high levels of the
cleaved forms of these caspases in control cells (Figure
9). In the AAV2 infected cells, simultaneous decline of
both uncleaved and cleaved forms of the three execu-
tioner caspases was potentially due to degradation by
non-caspase proteases as has been previously suggested
[66]. Specific cell death types have been attributed to
non-caspase proteases in multiple studies [67]. More-
over, PARP cleavage was not detected in AAV2 infected
MDA-MB-231 cells (Figure 9), further suggesting the
failure of AAV2 to activate executioner caspases. The
appearance of cleaved PARP is a measure of caspase
activity [68]. A switch from apoptosis to activation of
necrosis mediated cell death pathways could explain the
failure to cleave PARP [69] as well as the appearance of
non-specific DNA degradation mixed with the apoptotic
DNA ladders (Figure 1C). In contrast to the executioner
caspases, death of AAV2 infected MDA-MB-231 cells
on day 6 and day 7 was correlated with cleavage of the
initiator caspase-8 to its 28 kDa species and caspase-9
to 35 and 37 kDa proteolytic species (Figure 9). The
AAV2 regulated cleavage of caspase-9 implicated disrup-
tion of mitochondrial functions and release of cyto-
chrome c. On the other hand, the simultaneous cleavage
of caspase-8 in the AAV2 infected cells indicated the
activation of the extrinsic pathways of apoptosis. Cumu-
latively, our results suggests AAV2 mediated co-activa-
tion of the extrinsic and the intrinsic pathways of
apoptotic cell death in the MDA-MB-231 cells. In addi-
tion, simultaneous triggering of non-caspase protease
regulated cell death pathways cannot be ruled out.
Therefore, activation of multiple cell death pathways
could culminate in death of the MDA-MB-231 cells.
In comparison with all three breast cancer cell lines
tested, nHMECs infected with AAV2 did not show clea-
vage of initiator or executioner caspases tested (Fig-
ure 10), as would be expected from the inability of
AAV2 to express Rep proteins or undergo active replica-
tion in nHMECs. Cumulatively, our results presented
here suggest the ability of AAV2 to activate multiple
pathways of apoptosis, and potentially necrosis, in a
range of human breast cancer derived cell lines repre-
senting different grades of aggressiveness. However,
regardless of the mode of cell death implemented,
AAV2 infection cumulatively resulted in complete cell
death.
AAV2 Rep protein expression and apoptosis induction
also results in deregulation of cell cycle check-point
controls
Thus far, AAV2 mediated cell death failed to reveal any
common mechanisms of apoptosis among the different
breast cancer lines studied. Since mechanisms control-
ling cell proliferation and cell death are interconnected
Figure 9 AAV2 induction of apoptosis/cell death in MDA-MB-
231 cells results in activation of caspases of both the intrinsic
and extrinsic pathways but not PARP cleavage. Left panel: MDA-
MB-231 monolayer cell cultures were synchronized in G1, followed
by infection with AAV2. Cell pellets were collected each day over a
7 day period. Cells were passaged 1:2 on day 2 and day 5.
Detection of caspases and their cleavage/activation was performed
by Western blotting. Total protein extracts were prepared as
described previously [48]. Sixty micrograms of total protein extracts
from AAV2 infected and control MDA-MB-468 cells were resolved in
SDS-polyacrylamide gel electrophoresis (PAGE) gels. To detect the
35 kDa pro-caspase form of caspase-3, proteins were resolved in a
10% SDS-PAGE gel and detected with caspase-3 rabbit monoclonal
antibody (Cell Signaling Technology). To detect the17-kDa cleaved
caspase-3 forms, proteins were resolved in a 15% SDS-PAGE gel and
detected with rabbit polyclonal antibody against cleaved caspase-3
(Cell Signaling Technology). To detect the 35 kDa pro-caspase form
of caspase-6, proteins were resolved in a 10% SDS-PAGE gel and to
detect the 15 kDa cleaved form of caspase-6, proteins were
resolved in a 15% SDS-PAGE gel and detected with a rabbit
polyclonal antibody (Cell Signaling Technology). To detect both the
pro- and cleaved forms of caspase-7, caspase-8 and caspase-9,
proteins were resolved in a 10% SDS-PAGE gel. The 35 kDa pro-
caspase form and the 30 kDa/20 kDa cleaved forms of caspase-7
was detected with a mouse monoclonal antibody (Cell Signaling).
The pro-caspase and cleaved 28 kDa form of caspase-8 was
detected with a mouse monoclonal antibody (Alexis Biochemicals).
The 47 kDa pro-caspase and 37 kDa/35 kDa cleaved forms of
caspase-9 were detected with a rabbit polyclonal antibody (Cell
Signaling). To detect the pro- (116 kDa) form of PARP, proteins were
resolved in a 7.5% SDS-PAGE gel and detected with a rabbit
monoclonal antibody (Cell Signaling).
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Page 14 of 24[70-72], we next examined pathways of cell cycle pro-
gression. To determine whether apoptosis induction in
AAV2 infected breast cancer cells coincided with
changes in cell cycle progression, we performed fluores-
cence-activated cell sorting (FACS) analysis and deter-
mined the percentage distribution of mock and AAV2
infected cells in G1, S, G2 and M phases. We observed
a sustained increase in the percentage of AAV2 infected
MCF-7 cells entering into S phase on day 4 to day 7
compared with controls (Figure 11A). Increased S phase
entry occurred subsequent to Rep protein expression on
d a y3i nt h eA A V 2i n f e c t e dM C F - 7c e l l s( F i g u r e3 A ) .
Taken together, these results suggested Rep protein
mediated a breach of the G1/S check-point control
which allowed for the increased S phase entry and pro-
gression (Figure 11A) and apoptosis induction (Figure
1A). On day 3, Rep protein expression in AAV2 infected
MCF-7 cells (Figure 3) was correlated with steady-state
pRb protein expression displaying both the hyper-phos-
phorylated (inactive) and hypo-phosphorylated form of
this tumor suppressor (Figure 12A). The appearance of
the hyper-phosphorylated species of pRb in AAV2
infected cells could have at least two simultaneous con-
sequences on cell fate. First, pRb inactivation and E2F
release could result in E2F transcription of S phase
genes [73]. Second, DNA damage-induced pRb post-
translational modification and inactivation could also
promote E2F1 transcription of pro-apoptotic genes [74].
Therefore, in AAV2 infected MCF-7 cells, death could
occur due to conflicting signals arising from a breach of
G1/S checkpoints, followed by S phase entry and pro-
gression (compare Figure 11A and 12A), in the presence
of damaged DNA (Figure 1A). On day 3, Rep protein
expression in MCF-7 cells (Figure 3) also coincided with
decreased expression of the CDK inhibitors p21
WAF1
and p27
KIP1 (Figure 12A), thereby establishing condi-
tions resembling a cellular environment which is per-
missive for S phase entry [75]. Additionally, dropping
cellular p21
WAF1 protein levels decreases the ability of
cells to block apoptosis [76], and may act to prime the
AAV2 infected MCF-7 cells for downstream events
which culminate in apoptosis induction. We also deter-
mined levels of p53 protein expression, as in normal
cells p53 is a transcriptional activator of p21
WAF1 [77].
In the AAV2 infected MCF-7 cells, significant changes
in total p53 levels were not observed (Figure 12A).
However, a slower migrating band was detected with
the p53 antibody. This band could potentially represent
phosphorylated species of p53 known to be induced
upon activation of DNA damage signals [78]. These
results are not unexpected since the MCF-7 cells harbor
a normal p53 [79]. Finally, on day 5 to day 7, AAV2
infected MCF-7 cells undergoing apoptosis showed
decreased levels of the p16
INK4 tumor suppressor pro-
tein compared with controls (Figure 12A). In contrast,
control cells reached confluency and became contact
inhibited (Figure 11A). The observed AAV2 mediated




INK4, could be a mechanism necessary
to counteract cell cycle check-point regulated growth
arrest in AAV2 infected cells and induction of apoptosis.
In the AAV2 infected MDA-MB-231 cells, apoptosis
induction similarly coincided with increased S phase
entry (Figure 11C), but at a much later time point (day
6) in the time-course compared to the virus infected
MCF-7 cells (compare Figure 11A and 11C). However,
in contrast to the AAV2 infected MCF-7 cells, increased
S phase entry in AAV2 infected MDA-MB-231 cells was
marked with the appearance of hypo-phosphorylated
pRb (Figure 12C). Others have also reported the ability
of Rep78 to promote pRb hypo-phosphorylation and a
complete S phase arrest [40,80]. In the AAV2 infected
MDA-MB-231 cells, S phase entry and apoptosis induc-
tion also coincided with decreased levels of p21
WAF1,
Figure 10 AAV2 infection of nHMECs does not result in
activation of caspases of either the intrinsic and extrinsic
pathways of apoptosis. nHMEC monolayer cultures were
synchronized in G1 as described, followed by infection with AAV2.
Cell pellets were collected each day over a 5 day period. Cells were
passaged 1:2 on day 2. Detection of caspases and their cleavage/
activation was performed by Western blotting. Sixty micrograms of
total protein extracts from AAV2 infected and control nHMEC cells
were resolved in SDS-polyacrylamide gel electrophoresis (PAGE)
gels. To detect caspase-8 proteins were resolved in a 10% SDS-PAGE
gel and detected with a mouse monoclonal antibody (Alexis
Biochemicals). To detect the 35 kDa pro-caspase form of caspase-3,
proteins were resolved in a 10% SDS-PAGE gel and detected with
caspase-3 rabbit monoclonal antibody (Cell Signaling Technology).
To detect the pro- (116 kDa) form of PARP, proteins were resolved
in a 7.5% SDS-PAGE gel and detected with a rabbit monoclonal
antibody (Cell Signaling).
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Page 15 of 24Figure 11 Cell cycle progression and Fluorescence Activated Cell Sorting (FACS) analysis profiles of AAV2 infected breast cancer cell
lines. Cells were synchronized by trypsinization of 80% confluent cultures and plating at a density of 1 × 10
6 cells in E medium. The cells were
incubated for 10 to 12 h at which point at least two-thirds of the cells are maximally synchronized in the G1 phase. This time point was
designated time zero (t = 0). (A) MCF-7 (B) MDA-MB-468 and (C) MDA-MB-231 cells were infected with AAV2 at this point, and further cultured
over a 7-day period. Both control and AAV2 infected cells were passaged 1:2 on day 2 and day 5. On each day, cells were harvested by
trypsinization, washed with PBS, fixed in 70% ethanol, and stored at -20°C for 24 h. For performing FACS analysis, cells were resuspended in PBS
containing 0.1% Triton X-100, 200 μg/ml DNase-free RNase A, and 100 μg/ml of propidium iodide for 30 min at 37°C. Flow cytometric analysis of
10
6 cells was carried out in a fluorescence-activated cell sorter, and the percentages of cells in theG1, S and G2/M phases of the cell cycle were
determined using the Cell Quest program of Becton Dickinson. Data were analyzed with the Mod Fit LT program. For each cell line, FACS
analyses were repeated three times. Results shown represent averages determined from three individual experiments (-, no data), with standard
deviations presented in parentheses.
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Page 16 of 24Figure 12 AAV2 infection of different breast cancer cells and induction of apoptosis/cell death results in altered expression profiles of
different cell cycle tumor suppressors proteins. (A) MCF-7 (B) MDA-MB-468 and (C) MDA-MB-231 monolayer cell cultures were synchronized
by trypsinization of 80% confluent cultures and plating at a density of 1 × 10
6 cells in E medium. The cells were incubated for 10 to 12 h at
which point at least two-thirds of the cells are maximally synchronized in the G1 phase followed by infection with AAV2. This time point was
designated time zero (t = 0). Cell pellets were collected each day over a 7 day period. Cells were passaged 1:2 on day 2 and day 5. Detection of
cell cycle tumor suppressor proteins was performed by Western blotting. Total protein extracts were prepared as described previously [48]. Sixty
micrograms of total protein extracts from AAV2 infected and control cells were resolved in SDS-polyacrylamide gel electrophoresis (PAGE) gels.
The pRb protein hyperphosphorylated (Hyper-pRb) and hypophosphorylated (hypo-pRb) forms were detected using the rabbit polyclonal
antibody (Santa Cruz). The p21
WAF1, p27
KIP1 and p16
INK4 tumor suppressors were detecting using rabbit polyclonal antibodies (Santa Cruz) as
described in Materials and Methods. The p53 protein was detected using a mouse monoclonal antibody (Oncogene).
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KIP1, compared with con-
trols (Figure 12C). Overall, AAV2 induced cell death in
both the MCF-7 and MDA-MB-231 cell lines appeared
to target cell cycle check-point controls which poten-
tially mediate a breach in the G1/S cell cycle check-
point, further promoting entry of these cells into S
phase.
In contrast to the other two breast cancer cell lines,
AAV2 infected MDA-MB-468 cells increasingly entered
into G2 phase (day 3 to day 6) compared with unin-
fected cells (Figure 11B), which further coincided with
apoptotic DNA laddering (Figure 1B). During this time
frame, weak Rep protein expression could be observed
on day 3 through day 6 in AAV2 infected cells (Figure
3B). On day 7, Rep78 expression was increased com-
pared to day 6 and AAV2 infected apoptotic MDA-MB-
468 cells displayed an increased percentage of cells with
S phase DNA content compared with controls (Figure
11B). These results suggest that on day 7, increased
movement out of G2 into S phase coincided with strong
expression of Rep 78 on day 7 (Figure 3B). AAV2 regu-
lated cell cycle progression in the infected MDA-MB-
468 cells could not be correlated with significant
changes with pRb phosphorylation and the protein was
expressed in low levels (Figure 12B). Additionally, AAV2
infection of MDA-MB-468 cells did not induce signifi-




KIP1 protein levels were significantly
increased compared with controls (day 2 to day 7) (Fig-
ure 12B). Increased p27
KIP1 protein levels could poten-
tially mediate increased accumulation of these cells in
the G2 phase of the AAV2 infected cells undergoing
apoptosis (compare Figure 11B and 12B). Our results
suggest that AAV2 mediated G2 phase enrichment in
the MDA-MB-468 cells was sufficient for apoptosis
induction as determined from DNA laddering (Figure
1B), which occurred in the presence of low level Rep
protein expression (Figure 3B).
The differences in the kinetics of Rep protein expres-
sion and cell death among the three AAV2 infected
breast cancer cell lines appeared to synchronize with
selective enrichment of S phase specific functions. A
prominent requirement for G2 phase enrichment in the
MDA-MB-468 cells coincided with apoptotic DNA lad-
dering in the presence of low level Rep protein expres-
sion. Therefore, initiation of apoptosis could efficiently
occur in S or G2 phases in the breast cancer cell lines
tested. In the AAV2 infected MDA-MB-468 cells, Rep
78 expression was observed with clarity only on day 7
(Figure 3B) which also correlated with increased move-
ment into S phase (Figure 11B). Therefore, it is possible
that specific cellular functions which are conducive for
abundant Rep protein expression generally become
available upon S phase entry. Our results cumulatively
suggest that AAV2 targeting and enhanced activation of
key cell cycle check-points in G1/S, S and G2 phases
could be a cellular mechanism for Rep protein synthesis,
and further, could provide a priming mechanism for
inducing apoptosis in the different breast cancer derived
cell lines. The comparatively lower levels of Rep protein
expression in AAV2 infected MDA-MB-468 cells may
be one explanation as to why these cells arrest more in
G2 than in S phase.
AAV2 mediated manipulation of cell cycle check-points is
marked by upregulation of c-Myc and Ki-67 protein levels
Thus far, our results show that AAV2 induction of
apoptosis in the MCF-7 and MDA-MB-231 cells coin-
cided with pronounced S phase entry, whereas an initial
G2 phase enrichment followed by S phase entry was
observed in the MDA-MB-468 cells. Increased breach of
the G1/S check-point and movement of cells into S
phase is indicative of implementation of cellular prolif-
eration signals [81]. Likewise, increased G2 phase pro-
gression signals readiness of the cell to enter mitosis
[82]. AAV2 targeted interference with mechanisms
which control cell cycle check-points in cells undergoing
DNA damage could be a trigger for apoptosis induction.
Therefore, we reasoned that one or more signaling cas-
cades upstream of cell cycle controls could mechanisti-
cally couple both increased S and G2 phase progression,
proliferation and apoptosis induction.
In normal cells, entry of cells into the G1 phase and
execution of the G1/S cell cycle check-point is depen-
dent on multiple signaling mechanisms, a key regulator
of which is c-Myc [81]. On the other hand, PCNA and
Ki67 are markers of S phase proliferation [83,84]. We
performed western blots to detect the expression of
PCNA, Ki67 and c-Myc, in AAV2 infected breast cancer
cell lines tested. PCNA expression was found to be
increased in AAV2 infected MCF-7 and MDA-MB-468
cells compared with mock infected cells (day 1 to day 7)
(Figure 13A and 13B), but was somewhat decreased in
AAV2 infected MDA-MB-231 cells (Figure 13C). On
the other hand, Ki-67 expression was increased in all
the AAV2 infected breast cancer cells day 3 onwards
(Figure 13), which is indicative of signals for prolifera-
tion but which coincided with decreased cell viability
(Figure 2). Expression of c-Myc was greatly upregulated
in all AAV2 infected breast cancer cells starting on day
4 (Figure 13A-C). Both the dimer- and monomer forms
of c-Myc were detected in each cell line (Figure 13A-C).
Our results suggest that AAV2 regulated expression
and/or stabilization of c-Myc could serve to amplify pro-
liferation signals which allow the breast cancer cells to
bypass cell cycle checkpoint controls in the presence of
damaged cellular DNA. On the other hand, c-Myc is
also a well studied pro-apoptotic protein [85], which has
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Page 18 of 24Figure 13 AAV2 infection of different breast cancer cell lines and induction of apoptosis/cell death results in altered expression of
proliferation markers PCNA, Ki67 and c-Myc. (A) MCF-7 (B) MDA-MB-468 (C) MDA-MB-231 and (D) CIN-612 9E (HPV31b positive cervical
cancer cells) monolayer cell cultures were synchronized by trypsinization of 80% confluent cultures and plating at a density of 1 × 10
6 cells in E
medium. The cells were incubated for 10 to 12 h at which point at least two-thirds of the cells are maximally synchronized in the G1 phase
followed by infection with AAV2. This time point was designated time zero (t = 0). Cell pellets were collected each day over a 7 day period.
Cells were passaged 1:2 on day 2 and day 5. Detection of cell cycle proliferation proteins was performed by Western blotting. Total protein
extracts were prepared as described previously [48]. Sixty micrograms of total protein extracts from AAV2 infected and control cells were
resolved in SDS-polyacrylamide gel electrophoresis (PAGE) gels. The PCNA protein was detected using a rabbit polyclonal antibody (Santa Cruz).
The Ki67 protein was detected using a rabbit polyclonal antibody (Santa Cruz). The c-Myc protein was detected using a rabbit polyclonal
antibody (Santa Cruz).
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upon imposition of genotoxic stress [86] mediated via
the inherent endonuclease activity of AAV2 Rep78 and
Rep68 proteins [80]. Thus, in the breast cancer cell
lines, AAV2 regulation of c-Myc activation could poten-
tially mediate simultaneous growth stimulatory (G1/S, S
and G2 phase targeting), and growth inhibitory (apopto-
sis/necrosis associated DNA damage) signals which
could represent a central unifying mechanism of AAV2
induced cell death in multiple breast cancer types. In
addition, AAV2 infection also regulated increased c-Myc
and Ki67 expression in apoptotic HPV positive cervical
cancer lines (Figure 13D), suggesting that AAV2 imple-
ments common mechanisms of cell death in multiple
grades of breast cancer cells as well as in HPV positive
cervical cancer cells.
Discussion
The current study investigates the mechanisms by which
AAV2 induces apoptosis and/or cell death in the differ-
ent breast cancer cell lines. Overall, the significant find-
ing of this study was that while all three breast cancer
cell lines used underwent cell death in response to
AAV2, but not the primary breast epithelial cells, there
did not appear to be a “universal” pathway underlying
the demise of the three cancer lines. The underlying
molecular mechanism could involve the ability of the
AAV2 Rep proteins to push the cancer cells towards a
proliferative phenotype, as indicated by the increased
movement of cells into S (MCF-7 and MDA-MB-231
cells) and G2 phases (MDA-MB-468 cells), while simul-
taneously overcoming some DNA damage checkpoint
regulatory controls. In normal cells, DNA damage sig-
nals activate checkpoint kinases (Chk) play a critical role
in determining cellular responses to DNA damage by
initiating cell cycle arrest, thus allowing for DNA repair
[87]. The S, intra-S, and the G2-M phase checkpoints
are predominantly regulated by Chk1, whereas Chk2
regulates the G1 phase checkpoint [87]. In the current
study, addition of DNA damage via AAV2 genomic
inverted terminal repeats [88], or Rep protein nuclease
functions [80], could induce a significant level of cellular
stress, particularly in cancer cells which are already
compromised for DNA damage checkpoint functions
[87]. By promoting the virus infected breast cancer cell
lines to increasingly enter S and G2 phases in the pre-
sence of measurable DNA damage, potentially indicates
the ability of AAV2 to interfere with Chk1 kinase func-
tions. In a way, AAV2 action on the breast cancer cells
may be similar to the use of DNA damage checkpoint
kinase inhibitors which sensitize cancer cells to geno-
toxic chemotherapeutics, while non-cancerous cells are
more resistant to such therapeutics due to the intact
DNA damage checkpoint pathways.
AAV2 induced c-Myc expression is a regulator of both cell
proliferation and apoptosis
In the current study, we showed that multiple human
breast cancer derived cell lines representing both low
and high grades of aggressiveness, were permissive for
AAV2 replication and Rep protein expression, ultimately
resulting in 100% cell death. Common to all the breast
cancer cell lines tested, AAV2 mediated induction of
apoptosis coincided with upregulated expression of the
c-Myc protein, a transcription factor which is both a
regulator of cell proliferation as well as apoptosis [89].
Under normal conditions, c-Myc controls growth regu-
latory signals in early G1 and at the G1/S cell-cycle
check-points [90]. However, activity of c-Myc is also
deregulated in multiple cancers causing uncontrolled
cellular proliferation [91]. It has been shown that c-Myc
regulated processes of mitogenesis and apoptosis are
controlled by activation of disparate cellular machineries
[92]. Diverse stress-related signals such as growth factor
deprivation, hypoxia and exposure to genotoxic agents
have been shown to trigger c-Myc dependent apoptosis
[93]. Acute activation of c-Myc sensitizes cells to apop-
tosis by inducing cytochrome c release from the mito-
chondria through activation of the pro-apoptotic
members of the Bcl-2 family in cells deprived of growth
factors [94]. Additionally, overexpression of c-Myc was
shown to accelerate the apoptotic response by sensitiz-
ing cells to pro-apoptotic insults [95].
pRb phosphorylation status as a dual marker of AAV2
regulated proliferation and cell death
AAV2 induced apoptosis was correlated with increased
S-phase entry in the MCF-7 and MDA-MB-231 cells
which is likely due in part to the observed increased c-
Myc expression. Ectopic expression of c-Myc has been
shown to induce S phase entry in quiescent cells, obser-
vations which first suggested that c-Myc can play a role
in G1/S transition, similar to that observed for E2F1
[90]. However, the increased S phase entry observed had
cell specific consequences on the status of pRb phos-
phorylation. In the AAV2 infected MCF-7 cells, pRb
protein expression was stabilized displaying both hyper-
phosphorylated (inactive) and hypophosphorylated
(active) forms of the protein. Normally, pRb inactivation
and E2F release is required for E2F transcription of S-
phase genes [73]. However, DNA-damage-induced pRb
acetylation/inactivation promotes E2F1 transcription of
proapoptotic genes [74]. In contrast, DNA damage-
induced Chk2-mediated phosphorylation of pRb leads to
E2F sequestration and transcriptional inhibition of proa-
poptotic genes [96]. In the current study, we demon-
strated the ability of AAV2 to catalyze S-phase entry in
cycling MCF-7 cells in the presence of pRb in both its
active and inactive forms, which could represent a novel
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infected with AAV2, death could occur due to conflict-
ing signals arising from a breach of G1/S checkpoints,
followed by S-phase entry and progression (mediated by
hyperphosphorylated pRb), simultaneous with the tran-
scription of genes related to differentiation and grown
arrest (activated by hypophosphorylated pRb). On the
other hand, AAV2 infection of MDA-MB-231 cells
induced increased entry into S phase and displayed
hypophosphorylated pRb. Induction of necrosis as a
mode of cell death and associated energy depletion [97]
could result in the failure to maintain phosphorylated
species of pRb. Others have reported the ability of
Rep78 to promote pRb hypophosphorylation and a com-
plete S-phase arrest [40,80] mediated via Rep78 binding
to CDC25A and preventing access to its substrates,
CDK2 and CDK1 [40,80].
AAV2 modulates cellular tumor suppressor protein levels
to induce movement through S and G2 phases
It is notable that AAV2 triggered S-phase entry in MCF-
7 and MDA-MB-231 cells occurred in the presence of




INK4, conditions which would be expected to
enhance entry into S phase, and which could be a
mechanism whereby AAV2 competes with the cancer
cells for cellular factors for its own transcription. AAV2
mediated downregulation of p21
WAF1 levels may act to
prime the breast cancer cells for downstream events
which culminate in apoptosis. In support of our obser-
vations, antisense oligonucleotide to p21
WAF1 was
shown to attenuate p21
WAF1 levels and induce apoptosis
in MCF-7 cells [98]. On the other hand, the MDA-MB-
468 cells infected with AAV2 increasingly entered into
G2. Other reports indicate that c-Myc expression could
also cause G2/M arrest and mediate apoptosis induction
[99]. In normal cells, intact p53 and p21
WAF1 proteins
respond to DNA damage signaling by sustaining a G2-
phase arrest which is a protective cellular mechanism
for allowing DNA repair before proceeding into mitosis
[100]. However, apoptotic DNA laddering was observed
in AAV2 infected MDA-MB-468 cells which were
enriched in the G2 phase of the cell cycle in the pre-
sence of increased levels of p27
KIP1,w h i c hi nn o r m a l
cells has the potential to mediate growth arrest [101].
AAV2 regulated cell death does not result from activation
of common pathways of apoptosis
c-Myc is a potent inducer of apoptosis [85] and was
clearly expressed in all the AAV2 infected breast cancer
cell lines. However, our results showed that the final
stages of AAV2 induced cell death in the multiple breast
cancer cell lines was not due to activation of common
pathways of apoptosis. A major difference among the
different breast cancer cell lines used was the expression
of caspase-3. In the MCF-7 cells, the loss of caspase-3
has been shown to correlate with resistance to drug-
induced apoptosis in breast cancer cells [102]. In the
current study, induction of caspase-independent apopto-
tic cell death in MCF-7 cells potentially resulted from
AAV2-regulated pro-apoptotic signaling at the level of
the mitochondria resulting in the release of mitochon-
drial factors such as Apoptosis Inducing Factor (AIF)
from the intermembrane space, its translocation to the
nucleus, and subsequent triggering of nuclear apoptosis
by facilitating DNA fragmentation and chromatin con-
densation [103]. We also observed AAV2 specific PARP
cleavage in a caspase-independent manner, which could
be regulated by calpain, a Ca
2+-dependent intracellular
cysteine protease, a finding also previously reported in
oridonin treated MCF-7 cells [65]. In contrast, although
the MDA-MB-231 cell line expresses caspase-3, AAV2
infection of this cell line potentially resulted in a mix-
ture of caspase-dependent and -independent forms of
cell death. AAV2 mediated simultaneous cleavage of
both caspase-8 and caspase-9 suggesting activation of
the extrinsic and intrinsic pathways of apoptosis respec-
tively, however downstream activation of executioner
caspases could not be clearly defined due to non-specific
degradation of both their uncleaved and cleaved forms.
Since PARP cleavage was not observed in the AAV2
infected MDA-MB-231 cells, our results indirectly sug-
gested that the activity of executioner caspases could
have been inhibited in virus infected cells. Others have
reported that mechanistic inactivation of caspases causes
a shift from apoptosis to cell death consisting of mixed
necrotic/apoptotic features, or full-blown necrosis [104].
Activation of necrosis is a default pathway of cell death
which is unmasked when the apoptotic pathway is
inhibited [105]. Failure to observe PARP cleavage in the
AAV2 infected MDA-MB-231 cells not only highlights
absence of caspase activation, but also potentially sug-
gests activation of necrosis as mode of cell death and
agrees with observations in other published reports
[106]. In cells undergoing extensive DNA damage, cellu-
lar response to repair the DNA results in hyperactiva-
tion of PARP-1, which subsequently results in the
depletion of cytosolic NAD
+, and its precursor ATP,
leading to necrotic cell death via energy failure [97].
Additionally, since the completion of apoptosis is abso-
lutely dependent on the presence of ATP, upon its cellu-
lar depletion, cell death switches from apoptosis to
necrosis [107]. Thus, caspase-9 cleavage in AAV2
infected MDA-MB-231 cells undergoing DNA degrada-
tion indicates activation of apoptosis but failure to cleave
PARP is further indicative of the switch to necrosis. In
contrast, among the three cell lines, only the AAV2
infected MDA-MB-468 cell line resulted in caspase-9
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caspase-3 and PARP cleavage.
Cumulatively, our results suggest that AAV2 regu-
lated Rep protein expression leads to cell death. Our
present findings have relevance for understanding the
mechanisms of AAV2 induction of complete cell death
in breast cancer cells as well as studying mechanisms
of resistance to breast cancer therapy. By regulating
the expression of c-Myc, AAV2 potentially targets a
central protein which regulates multiple processes of
cell survival, cell cycle and apoptosis [90] in the multi-
ple breast cancer lines. An additional c-Myc regulated
effector acting upstream of the mitochondrial apopto-
tic machinery is Ataxia telangiectasia mutated (ATM)-
dependent DNA damage checkpoint responses in
response to genotoxic stress [86]. Incidentally, AAV2
Rep 78 and Rep 68 mediated nicking of cellular chro-
matin has also been shown to induce a DNA damage
response via activation of ATM [80]. Thus, AAV2
could serve to further sensitize c-Myc regulated pro-
apoptotic functions.
Conclusions
The cellular links between cell survival, cell death and
cell cycle have been recently reviewed [108]. In the
current study, our results highlight the ability of AAV2
to regulate cell cycle and activate multiple routes of
apoptotic cell death, which could provide insights into
understanding the cellular mechanisms of drug resis-
tance and global targeting of breast cancer. On the
other hand, AAV2 infected nHMECs failed to undergo
productive AAV2 replication and the failure of AAV2
to productively infect normal epithelial cells could be
clinically advantageous and potentially portrays AAV2
as an ideal biological therapeutic. Our results suggest
the potential for AAV2 to be developed as therapeutics
for multiple types of breast cancer. Further, under-
standing the molecular mechanisms central to AAV2
targeting of cell death pathways in breast cancer
derived cell lines will help in the design of more effec-
tive therapeutics irrespective of the type and grade of
breast cancer.
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